StudyFinder
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection in Patients with Locally Advanced or Metastatic Solid Tumours
Status: Recruiting
This is an early study of a new drug, called [225Ac]-FPI-1434, to treat solid tumors that have not responded to usual treatment. We are testing different doses of the drug and looking at how well it works for treating the cancer and side effects that occur.
Age: 18 years and over
Healthy Volunteers:
Inclusion Criteria:
• advanced solid tumor that is refractory to all standard treatment, for which no standard treatment is available, or it is contraindicated, or the patient refuses standard therapy
• restricted in strenuous activity but can walk and is able to do light work e.g., light house work, office work
• contact study staff for additional requirements
Exclusion Criteria:
• inability to perform the required imaging procedures (e.g., inability to lay flat during scan time)
• uncontrolled brain metastasis
• history of organ transplantation, including stem cell transplantation
• other significant medical or mental health diagnosis (study staff will review)
Interventions:
Biological: FPI-1175 Infusion, Drug: [111In]-FPI-1547 Injection, Drug: [225Ac]-FPI-1434 Injection multi-dose, Drug: [225Ac]-FPI-1434 Injection single-dose
Conditions:
Cancer
Keywords:
Clinics and Surgery Center (CSC), Advanced Solid Tumors
Contact(s): Douglas Yee - yeexx006@umn.edu
Principal Investigator: Douglas Yee, MD
Phase: PHASE1
IRB Number: STUDY00013618
System ID: 34662
See this study on ClinicalTrials.gov